Meeting report

FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients

Robert Ettenger, Renata Albrecht, Rita Alloway, Ozlem Belen, Marc W. Cavaillé-Coll, Marie Chisholm-Burns, Mary Amanda Dew, William E. Fitzsimmons, Peter Nickerson, Graham Thompson, Pujita Vaidya

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Food and Drug Administration (FDA) held a public meeting and scientific workshop in September 2016 to obtain perspectives from solid organ transplant recipients, family caregivers, and other patient representatives. The morning sessions focused on the impact of organ transplantation on patients’ daily lives and the spectrum of activities undertaken to maintain grafts. Participants described the physical, emotional, and social impacts of their transplant on daily life. They also discussed their posttransplant treatment regimens, including the most burdensome side effects and their hopes for future treatment. The afternoon scientific session consisted of presentations on prevalence and risk factors for medication nonadherence after transplantation in adults and children, and interventions to manage it. As new modalities of Immunosuppressive Drug Therapy are being developed, the patient perceptions and input must play larger roles if organ transplantation is to be truly successful.

Original languageEnglish (US)
Pages (from-to)564-573
Number of pages10
JournalAmerican Journal of Transplantation
Volume18
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Medication Adherence
United States Food and Drug Administration
Organ Transplantation
Transplants
Hope
Pharmaceutical Preparations
Patient Advocacy
Immunosuppressive Agents
Social Change
Caregivers
Transplantation
Education
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Meeting report : FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients. / Ettenger, Robert; Albrecht, Renata; Alloway, Rita; Belen, Ozlem; Cavaillé-Coll, Marc W.; Chisholm-Burns, Marie; Dew, Mary Amanda; Fitzsimmons, William E.; Nickerson, Peter; Thompson, Graham; Vaidya, Pujita.

In: American Journal of Transplantation, Vol. 18, No. 3, 01.03.2018, p. 564-573.

Research output: Contribution to journalArticle

Ettenger, R, Albrecht, R, Alloway, R, Belen, O, Cavaillé-Coll, MW, Chisholm-Burns, M, Dew, MA, Fitzsimmons, WE, Nickerson, P, Thompson, G & Vaidya, P 2018, 'Meeting report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients', American Journal of Transplantation, vol. 18, no. 3, pp. 564-573. https://doi.org/10.1111/ajt.14635
Ettenger, Robert ; Albrecht, Renata ; Alloway, Rita ; Belen, Ozlem ; Cavaillé-Coll, Marc W. ; Chisholm-Burns, Marie ; Dew, Mary Amanda ; Fitzsimmons, William E. ; Nickerson, Peter ; Thompson, Graham ; Vaidya, Pujita. / Meeting report : FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients. In: American Journal of Transplantation. 2018 ; Vol. 18, No. 3. pp. 564-573.
@article{39800b85a3584b78839aebab207d4ab5,
title = "Meeting report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients",
abstract = "The Food and Drug Administration (FDA) held a public meeting and scientific workshop in September 2016 to obtain perspectives from solid organ transplant recipients, family caregivers, and other patient representatives. The morning sessions focused on the impact of organ transplantation on patients’ daily lives and the spectrum of activities undertaken to maintain grafts. Participants described the physical, emotional, and social impacts of their transplant on daily life. They also discussed their posttransplant treatment regimens, including the most burdensome side effects and their hopes for future treatment. The afternoon scientific session consisted of presentations on prevalence and risk factors for medication nonadherence after transplantation in adults and children, and interventions to manage it. As new modalities of Immunosuppressive Drug Therapy are being developed, the patient perceptions and input must play larger roles if organ transplantation is to be truly successful.",
author = "Robert Ettenger and Renata Albrecht and Rita Alloway and Ozlem Belen and Cavaill{\'e}-Coll, {Marc W.} and Marie Chisholm-Burns and Dew, {Mary Amanda} and Fitzsimmons, {William E.} and Peter Nickerson and Graham Thompson and Pujita Vaidya",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/ajt.14635",
language = "English (US)",
volume = "18",
pages = "564--573",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Meeting report

T2 - FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients

AU - Ettenger, Robert

AU - Albrecht, Renata

AU - Alloway, Rita

AU - Belen, Ozlem

AU - Cavaillé-Coll, Marc W.

AU - Chisholm-Burns, Marie

AU - Dew, Mary Amanda

AU - Fitzsimmons, William E.

AU - Nickerson, Peter

AU - Thompson, Graham

AU - Vaidya, Pujita

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The Food and Drug Administration (FDA) held a public meeting and scientific workshop in September 2016 to obtain perspectives from solid organ transplant recipients, family caregivers, and other patient representatives. The morning sessions focused on the impact of organ transplantation on patients’ daily lives and the spectrum of activities undertaken to maintain grafts. Participants described the physical, emotional, and social impacts of their transplant on daily life. They also discussed their posttransplant treatment regimens, including the most burdensome side effects and their hopes for future treatment. The afternoon scientific session consisted of presentations on prevalence and risk factors for medication nonadherence after transplantation in adults and children, and interventions to manage it. As new modalities of Immunosuppressive Drug Therapy are being developed, the patient perceptions and input must play larger roles if organ transplantation is to be truly successful.

AB - The Food and Drug Administration (FDA) held a public meeting and scientific workshop in September 2016 to obtain perspectives from solid organ transplant recipients, family caregivers, and other patient representatives. The morning sessions focused on the impact of organ transplantation on patients’ daily lives and the spectrum of activities undertaken to maintain grafts. Participants described the physical, emotional, and social impacts of their transplant on daily life. They also discussed their posttransplant treatment regimens, including the most burdensome side effects and their hopes for future treatment. The afternoon scientific session consisted of presentations on prevalence and risk factors for medication nonadherence after transplantation in adults and children, and interventions to manage it. As new modalities of Immunosuppressive Drug Therapy are being developed, the patient perceptions and input must play larger roles if organ transplantation is to be truly successful.

UR - http://www.scopus.com/inward/record.url?scp=85042323601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042323601&partnerID=8YFLogxK

U2 - 10.1111/ajt.14635

DO - 10.1111/ajt.14635

M3 - Article

VL - 18

SP - 564

EP - 573

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 3

ER -